5α-reductase 2 polymorphisms as risk factors in prostate cancer

Pharmacogenetics

Volumn 12, Issue 4, 2002, Pages 307-312

  Söderström, Torbjörn ^a   Wadelius, Mia ^a   Andersson, Swen Olov ^a   Johansson, Jan Erik ^a   Johansson, Sara ^a   Granath, Fredrik ^a   Rane, Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 reductase 2; Metastasis; Polymorphism; Prostate cancer

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; DNA; PRIMER DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CANCER RISK; CATALYSIS; CELL DIFFERENTIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; RISK FACTOR; TARGET CELL; AGE; ALLELE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CAUCASIAN; CHEMISTRY; ENZYMOLOGY; GENETICS; GENOTYPE; HETEROZYGOTE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; RISK; SWEDEN;

AGE FACTORS; AGED; ALLELES; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DNA; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0036016312     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200206000-00006     Document Type: Article

References (28)

1. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
2. Prostate cancer associated with CYP17 genotype
3. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
4. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
5. Prostate Cancer Prevention Trial (PCPT) update
6. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer
7. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase
8. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
9. Biochemical and pharmacogenetic dissection of human steroid 5alpha-reductase type II
10. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay
11. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions
12. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer
13. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer
14. The TNM classification of prostate cancer
15. Prognostic factors in metastatic prostate cancer
16. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer
17. The war on cancer
18. Early detection of prostate cancer
19. Prostate carcinoma: Production of bioactive factors
20. Prognostic factors in metastatic prostate cancer
21. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer
22. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies
23. Regulation of urokinase production by androgens in human prostate cancer cells: Effect on tumor growth and metastases in vivo
24. Patient age as a prognostic factor in prostate cancer
25. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support
26. Prostate cancer screening: The problem of overdiagnosis and lessons to be learned from breast cancer screening